Tyme Technologies, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-29: Form 8-K; Period of report 2021-12-22; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2021-12-14: Form 8-K; Period of report 2021-12-14; Description 8.01 Other Events; Details 8.01.
- 2021-11-08: Form 8-K; Period of report 2021-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-08-26: Form 8-K; Period of report 2021-08-24; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events; Details 5.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-29 | 8-K | 2021-12-22 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On December 22, 2021, the Company received notice from The Nasdaq Stock Market (“Nasdaq”) that the closing bid price for our common stock had been below $1.00 per share for the previous 30 consecutive business days, and that we are therefore not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). | d222237d8k.htm |
| 2021-12-14 | 8-K | 2021-12-14 | 8.01 Other Events | 8.01 A copy of TYME’s press release dated December 14, 2021, attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing preclinical data on the effect of TYME-19 in SARS CoV-2 infections, is incorporated herein by reference. | d121082d8k.htm |
| 2021-11-08 | 8-K | 2021-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2021, TYME released financial information for the fiscal quarter ended September 30, 2021. | d245012d8k.htm |
| 2021-08-26 | 8-K | 2021-08-24 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.03 On August 24, 2021, our Board of Directors (the “Board”) amended and restated the Company’s amended and restated by-laws (the “A&R By-laws”) to provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) will be the exclusive forum for actions or proceedings for: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a breach of fiduciary duty owed to the Company or its stockholders; (iii) any action asserting a claim against us arising under the Delaware General Corporation Law, the Company’s certificate of incorporation, or the A&R By-laws; or (iv) any action asserting a claim against the Company that is governed by the internal affairs doctrine. 8.01 On August 24, 2021, the Board approved and adopted Corporate Governance Guidelines for the Company. | d528599d8k.htm |
| 2021-08-10 | 8-K | 2021-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2021, TYME released financial information for the fiscal quarter ended June 30, 2021. | d137924d8k.htm |
| 2021-06-21 | 8-K | 2021-06-15 | 8.01 Other Events | 8.01 On June 17, 2021, our Chief Science Officer, Steve Hoffman, entered into an individual written trading plan (the “10b5-1 Plan”) in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and our insider trading policy. | d141141d8k.htm |
| 2021-06-10 | 8-K | 2021-06-10 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On June 10, 2021, TYME released financial information for the year ended March 31, 2021. 8.01 As previously disclosed, in January 2021, Tyme initiated a comprehensive strategic review to assess the Company’s existing opportunities, explore untapped opportunities that may have been overlooked and maximize the efficiency of our capital expenditures in an effort to unlock TYME’s full potential. | d120366d8k.htm |
| 2021-05-13 | 8-K | 2021-05-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 13, 2021, the Board of Directors of the Company (the “Board”) appointed Frank L. Porfido as the new Chief Financial Officer of the Company, to be effective on the second business day following the filing of the Company’s Annual Report on Form 10-K for the year ended March 31, 2021. | d137470d8k.htm |
| 2021-04-01 | 8-K | 2021-04-01 | 8.01 Other Events | 8.01 A copy of the press release, attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing the resignation of Dr. Giuseppe Del Priore, Chief Medical Officer (“CMO”) of TYME, effective March 31, 2021, and the appointment of Dr. Jan M Van Tornout as acting CMO, effective April 1, 2021, is incorporated herein by reference. | d35964d8k.htm |
| 2021-02-05 | 8-K | 2021-02-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d116666d8k.htm |